<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015312</url>
  </required_header>
  <id_info>
    <org_study_id>TAME-AL</org_study_id>
    <secondary_id>2012-004520-38</secondary_id>
    <nct_id>NCT02015312</nct_id>
  </id_info>
  <brief_title>A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)</brief_title>
  <acronym>TAME-AL</acronym>
  <official_title>A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florian Michel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid&#xD;
      light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest&#xD;
      posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 11, 2017</completion_date>
  <primary_completion_date type="Actual">October 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the 12 month change in left ventricular mass</measure>
    <time_frame>12 month</time_frame>
    <description>The primary analysis to compare the 12 month change in left ventricular mass between the two treatment arms will be performed by a one-sided two-sample t test at a significance level of 0.025.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline, 12 month</time_frame>
    <description>Quality of Life, evaluated with EORTC-QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of EGCG</measure>
    <time_frame>12 month</time_frame>
    <description>Number of adverse events according to CTC criteria (Version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in cardiac biomarkers</measure>
    <time_frame>Baseline, 12 Month</time_frame>
    <description>cardiac troponin T (hsTNT), NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of hematological remission</measure>
    <time_frame>Baseline, 12 Month</time_frame>
    <description>Hematological Response according to Palladini et al 2012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response in affected organs other than heart</measure>
    <time_frame>Baseline, 12 Month</time_frame>
    <description>Organ response according to Gertz et al 2005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Light Chain (AL) Amyloidosis</condition>
  <condition>Cardiac Involvement</condition>
  <arm_group>
    <arm_group_label>Epigallocatechin-3-gallate (EGCG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules&#xD;
Dose:&#xD;
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epigallocatechin-3-gallate (EGCG)</intervention_name>
    <description>Pharmaceutical formulation: capsules&#xD;
Dose:&#xD;
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months</description>
    <arm_group_label>Epigallocatechin-3-gallate (EGCG)</arm_group_label>
    <other_name>Epigallocatechin gallate</other_name>
    <other_name>EGCG</other_name>
    <other_name>Epigallocatechin 3-gallate</other_name>
    <other_name>Tea catechin</other_name>
    <other_name>Epigallocatechin-3-gallate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical formulation: capsules&#xD;
Dose:&#xD;
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Mannitol 99.5% + highly dispersed silicon dioxide 0.5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven systemic AL amyloidosis.&#xD;
&#xD;
          -  Cardiac involvement with septum thickness more than 12 mm (without other causes as&#xD;
             published by Gertz et al., hypertension or other potential causes of left ventricular&#xD;
             hypertrophy)&#xD;
&#xD;
          -  Previously treated with chemotherapy, induced at least a very good partial remission&#xD;
             of the underlying monoclonal plasma cell or B cell disorder.&#xD;
&#xD;
          -  GPT and GOT less than 3-times ULN.&#xD;
&#xD;
          -  Life expectancy more than 12 month.&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trail.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  For women with childbearing potential and men, adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years.&#xD;
&#xD;
          -  Concomitant multiple myeloma stage 2 and 3 (Salmon and Durie)&#xD;
&#xD;
          -  Concurrent chemotherapy necessary&#xD;
&#xD;
          -  Time to last chemotherapy more than 6 months.&#xD;
&#xD;
          -  Chronic liver disease, Bilirubin over 1,5 mg/dl&#xD;
&#xD;
          -  Not able to visit Amyloidosis Clinic in Heidelberg every 3 months.&#xD;
&#xD;
          -  History of hypersensitivity to the investigational product or to any substance with&#xD;
             similar chemical structure or to any excipient present in the pharmaceutical form of&#xD;
             the investigational medicinal product.&#xD;
&#xD;
          -  Participation in other clinical trials or observation period of competing trials,&#xD;
             respectively.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schönland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Heidelberg; Medical Department V</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Florian Michel</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
    <mesh_term>Epigallocatechin gallate</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

